Stanford University
Showing 41-50 of 184 Results
-
Ron Dror
Cheriton Family Professor and Professor, by courtesy, of Structural Biology and of Molecular & Cellular Physiology
Current Research and Scholarly InterestsMy lab’s research focuses on computational biology, with an emphasis on 3D molecular structure. We combine two approaches: (1) Bottom-up: given the basic physics governing atomic interactions, use simulations to predict molecular behavior; (2) Top-down: given experimental data, use machine learning to predict molecular structures and properties. We collaborate closely with experimentalists and apply our methods to the discovery of safer, more effective drugs.
-
Alexander Dunn
Professor of Chemical Engineering
Current Research and Scholarly InterestsMy lab is deeply interested in uncovering the physical principles that underlie the construction of complex, multicellular animal life.
-
Oliv Eidam
Affiliate, Innovative Medicines Accelerator (IMA)
BioDr. Oliv Eidam is an accomplished computational scientist with over a decade of experience in drug discovery within biotech and pharmaceutical industries. As the Director of CADD Consulting GmbH, he leverages expertise in molecular modeling, data science, and cloud computing to drive innovation in drug development. His work has contributed to the successful IPOs of leading biotech firms and the advancement of clinical-stage therapeutics. A passionate leader, Dr. Eidam has built cross-disciplinary teams and authored over 20 high-impact publications and patents. He holds a Ph.D. in Structural Biology from the University of Zurich.
-
Alice C. Fan
Associate Professor of Medicine (Oncology) and, by courtesy, of Urology
Current Research and Scholarly InterestsDr. Fan is a physician scientist who studies how turning off oncogenes (cancer genes) can cause tumor regression in preclinical and clinical translational studies. Based on her findings, she has initiated clinical trials studying how targeted therapies affect cancer signals in kidney cancer and low grade lymphoma. In the laboratory, she uses new nanotechnology strategies for tumor diagnosis and treatment to define biomarkers for personalized therapy.
-
Rongxin Fang
Assistant Professor of Neurosurgery and, by courtesy, of Genetics
BioRongxin Fang received his Ph.D. in Bioinformatics and Systems Biology from the University of California, San Diego, under the mentorship of Bing Ren (2015–2019). During his doctoral training, he developed high-throughput genomic technologies and computational tools to map the structure and activity of the mammalian genome at large scale and single-cell resolution. He then applied these approaches to investigate how cis-regulatory elements - such as enhancers - control gene expression and drive the diverse transcriptional programs underlying cellular diversity in the mammalian brain. As an HHMI–Damon Runyon Postdoctoral Fellow at Harvard University (2019–2024). Rongxin developed and applied genome-scale, volumetric 3D transcriptome imaging methods to map the molecular and cellular architecture of the mammalian brain across evolution and aging. He also contributed to the collaboration with Adam Cohen and Catherine Dulac to integrate transcriptome imaging with functional neuronal imaging, identifying neuronal populations in the animal brain that underlie specific brain functions.
-
Dean W. Felsher
Professor of Medicine (Oncology) and of Pathology
Current Research and Scholarly InterestsMy laboratory studies the molecular basis of cancer with a focus on understanding when cancer can be reversed through targeted oncogene inactivation.
-
Daniel Fernandez
Director of Crystallography, Sarafan ChEM-H
BioSome say that proteins are spaghetti-like and wiggly. I use X-rays, crystals, and crystallography to "see" the atoms that make up things like spaghetti.
-
Michael Fischbach
Liu (Liao) Family Professor
Current Research and Scholarly InterestsThe microbiome carries out extraordinary feats of biology: it produces hundreds of molecules, many of which impact host physiology; modulates immune function potently and specifically; self-organizes biogeographically; and exhibits profound stability in the face of perturbations. Our lab studies the mechanisms of microbiome-host interactions. Our approach is based on two technologies we recently developed: a complex (119-member) defined gut community that serves as an analytically manageable but biologically relevant system for experimentation, and new genetic systems for common species from the microbiome. Using these systems, we investigate mechanisms at the community level and the strain level.
1) Community-level mechanisms. A typical gut microbiome consists of 200-250 bacterial species that span >6 orders of magnitude in relative abundance. As a system, these bacteria carry out extraordinary feats of metabolite consumption and production, elicit a variety of specific immune cell populations, self-organize geographically and metabolically, and exhibit profound resilience against a wide range of perturbations. Yet remarkably little is known about how the community functions as a system. We are exploring this by asking two broad questions: How do groups of organisms work together to influence immune function? What are the mechanisms that govern metabolism and ecology at the 100+ strain scale? Our goal is to learn rules that will enable us to design communities that solve specific therapeutic problems.
2) Strain-level mechanisms. Even though gut and skin colonists live in communities, individual strains can have an extraordinary impact on host biology. We focus on two broad (and partially overlapping) categories:
Immune modulation: Can we redirect colonist-specific T cells against an antigen of interest by expressing it on the surface of a bacterium? How do skin colonists induce high levels of Staphylococcus-specific antibodies in mice and humans?
Abundant microbiome-derived molecules: By constructing single-strain/single-gene knockouts in a complex defined community, we will ask: What are the effects of bacterially produced molecules on host metabolism and immunology? Can the molecular output of low-abundance organisms impact host physiology?
3) Cell and gene therapy. We have begun two new efforts in mammalian cell and gene therapies. First, we are developing methods that enable cell-type specific delivery of genome editing payloads in vivo. We are especially interested in delivery vehicles that are customizable and easy to manufacture. Second, we have begun a comprehensive genome mining effort with an emphasis on understudied or entirely novel enzyme systems with utility in mammalian genome editing.
